Automated Lugano Metabolic Response Assessment in 18F-Fluorodeoxyglucose-Avid Non-Hodgkin Lymphoma With Deep Learning on 18F-Fluorodeoxyglucose-Positron Emission Tomography

被引:7
|
作者
Jemaa, Skander [1 ]
Ounadjela, Souhila [1 ]
Wang, Xiaoyong [1 ]
El-Galaly, Tarec C. [2 ,3 ,4 ,5 ]
Kostakoglu, Lale [6 ]
Knapp, Andrea [7 ]
Ku, Grace [1 ]
Musick, Lisa [1 ]
Sahin, Denis [7 ]
Wei, Michael C. [1 ]
Yin, Shen [1 ]
Bengtsson, Thomas [8 ]
De Crespigny, Alex [1 ]
Carano, Richard A. D. [1 ]
机构
[1] Genentech Inc, South San Francisco, CA 94080 USA
[2] Aalborg Univ Hosp, Dept Hematol, Aalborg, Denmark
[3] Odense Univ Hosp, Dept Hematol, Hematol Res Unit, Odense, Denmark
[4] Univ Southern Denmark, Dept Clin Res, Odense, Denmark
[5] AI Sweden, Lund, Sweden
[6] Univ Virginia, Dept Radiol & Med Imaging, Charlottesville, VA USA
[7] F Hoffmann La Roche, Basel, Switzerland
[8] Univ Calif Berkeley, Dept Stat, Berkeley, CA USA
关键词
ARTIFICIAL-INTELLIGENCE; LUNG-CANCER; PET/CT; DLBCL; CONSENSUS; CRITERIA;
D O I
10.1200/JCO.23.01978
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE Artificial intelligence can reduce the time used by physicians on radiological assessments. For F-18-fluorodeoxyglucose-avid lymphomas, obtaining complete metabolic response (CMR) by end of treatment is prognostic. METHODS Here, we present a deep learning-based algorithm for fully automated treatment response assessments according to the Lugano 2014 classification. The proposed four-stage method, trained on a multicountry clinical trial (ClinicalTrials.gov identifier: NCT01287741) and tested in three independent multicenter and multicountry test sets on different non-Hodgkin lymphoma subtypes and different lines of treatment (ClinicalTrials.gov identifiers NCT02257567, NCT02500407; 20% holdout in ClinicalTrials.gov identifier NCT01287741), outputs the detected lesions at baseline and follow-up to enable focused radiologist review. RESULTS The method's response assessment achieved high agreement with the adjudicated radiologic responses (eg, agreement for overall response assessment of 93%, 87%, and 85% in ClinicalTrials.gov identifiers NCT01287741, NCT02500407, and NCT02257567, respectively) similar to inter-radiologist agreement and was strongly prognostic of outcomes with a trend toward higher accuracy for death risk than adjudicated radiologic responses (hazard ratio for end of treatment by-model CMR of 0.123, 0.054, and 0.205 in ClinicalTrials.gov identifiers NCT01287741, NCT02500407, and NCT02257567, compared with, respectively, 0.226, 0.292, and 0.272 for CMR by the adjudicated responses). Furthermore, a radiologist review of the algorithm's assessments was conducted. The radiologist median review time was 1.38 minutes/assessment, and no statistically significant differences were observed in the level of agreement of the radiologist with the model's response compared with the level of agreement of the radiologist with the adjudicated responses. CONCLUSION These results suggest that the proposed method can be incorporated into radiologic response assessment workflows in cancer imaging for significant time savings and with performance similar to trained medical experts.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Tuberculous Encephalitis with Aphemia Detected Only by 18F-Fluorodeoxyglucose-Positron Emission Tomography
    Maramattom, Boby Varkey
    Thomas, Joe
    Joseph, Surya
    ANNALS OF INDIAN ACADEMY OF NEUROLOGY, 2019, 22 (04) : 527 - +
  • [22] Sialadenoma papilliferum in the buccal mucosa detected on 18F-fluorodeoxyglucose-positron emission tomography
    Miyamoto, S.
    Ogawa, T.
    Chikazu, D.
    BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, 2017, 55 (07): : 727 - 729
  • [23] Arterial Inflammation Detected With 18F-Fluorodeoxyglucose-Positron Emission Tomography in Rheumatoid Arthritis
    Geraldino-Pardilla, Laura
    Zartoshti, Afshin
    Ozbek, Ayse Bag
    Giles, Jon T.
    Weinberg, Richard
    Kinkhabwala, Mona
    Bokhari, Sabahat
    Bathon, Joan M.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70 (01) : 30 - 39
  • [24] 18 Fluoride-fluorodeoxyglucose positron emission tomography in initial staging and response assessment of primary non-Hodgkin lymphoma of the tibia
    Harisankar, Chidambaram Natrajan Balasubramanian
    John, Jijoe
    Lekshmi, Thattaamuriyil Padmakumari
    Warrier, Arun
    INDIAN JOURNAL OF NUCLEAR MEDICINE, 2014, 29 (04): : 260 - 261
  • [25] Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL)
    Jerusalem, G
    Beguin, Y
    Najjar, F
    Hustinx, R
    Fassotte, MF
    Rigo, P
    Fillet, G
    ANNALS OF ONCOLOGY, 2001, 12 (06) : 825 - 830
  • [26] Noninvasive assessment of pediatric inflammatory bowel disease with 18F-fluorodeoxyglucose-positron emission tomography and computed tomography
    Daebritz, Jan
    Jasper, Niklas
    Loeffler, Markus
    Weckesser, Matthias
    Foell, Dirk
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2011, 23 (01) : 81 - 89
  • [27] The role of 18F-fluorodeoxyglucose-positron emission tomography in the assessment of disease activity in patients with takayasu arteritis
    Lee, Kwang-Hoon
    Cho, Arthur
    Choi, Yun-Jung
    Lee, Sang-Won
    Ha, You-Jung
    Jung, Se-Jin
    Park, Min-Chan
    Lee, Jong-Doo
    Lee, Soo-Kon
    Park, Yong-Beom
    ARTHRITIS AND RHEUMATISM, 2012, 64 (03): : 866 - 875
  • [28] Gallbladder lymphoma detected by 18F-fluorodeoxyglucose positron emission tomography
    So, Alvin
    Sheldon, James
    Kua, Hock
    WORLD JOURNAL OF NUCLEAR MEDICINE, 2020, 19 (04) : 428 - 431
  • [29] Prognostic significance of 18F-fluorodeoxyglucose positron emission tomography in lymphoma
    Weihrauch, MR
    Dietlein, M
    Schicha, H
    Diehl, V
    Tesch, H
    LEUKEMIA & LYMPHOMA, 2003, 44 (01) : 15 - 22
  • [30] Positron emission tomography in non-Hodgkin's lymphoma:: Assessment of chemotherapy with fluorodeoxyglucose
    Römer, W
    Hanauske, AR
    Ziegler, S
    Thödtmann, R
    Weber, W
    Fuchs, C
    Enne, W
    Herz, M
    Nerl, C
    Garbrecht, M
    Schwaiger, M
    BLOOD, 1998, 91 (12) : 4464 - 4471